Advertisement

Advertisement

NCCN 2019 Annual Congress: Hematologic Malignancies

multiple myeloma
immunotherapy

Jorge J. Castillo, MD, on Evolution of Therapy for Relapsed/Refractory Multiple Myeloma

Jorge J. Castillo, MD, of Dana-Farber Cancer Institute, discusses the many advances in treating relapsed and/or refractory multiple myeloma, including novel immunomodulators, proteasome inhibitors, an...

myelodysplastic syndromes

Rafael Bejar, MD, PhD, on Myelodysplastic Syndromes: Advances in Personalized Therapeutic Approaches

Rafael Bejar, MD, PhD, of the University of California, San Diego Moores Cancer Center, discusses the tailored nature of MDS treatment, including somatic mutations that could alter treatment decisions...

multiple myeloma

Nina Shah, MD: How Long Should Initial Treatment for Myeloma Last?

Nina Shah, MD, of the University of California, San Francisco, discusses the debate on fixed duration vs waiting until disease progression, a key question for clinicians treating patients with multipl...

lymphoma
immunotherapy

Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

Richard I. Fisher, MD, of Fox Chase Cancer Center, discusses the improvement in survival for patients with follicular lymphoma, new targeted biologic agents providing alternative treatments, and chemo...

leukemia
immunotherapy

Nitin Jain, MD, on CLL: Is There a Role for Chemoimmunotherapy?

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses the debate on evolving strategies in first-line treatment of CLL.

leukemia
immunotherapy

William G. Wierda, MD, PhD, on Evolving Strategies for First-Line Treatment of CLL

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, offers commentary on the debate about evolving strategies in first-line chronic lymphocytic leukemia, the clinical tri...

hematologic malignancies

Andrew D. Zelenetz, MD, PhD, on The Era of Therapeutic Biosimilars: What You Need to Know

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the nature of biologic molecules and their importance in future therapeutic innovation.

Advertisement

Advertisement



Advertisement